Zobrazeno 1 - 10
of 224
pro vyhledávání: '"NAOHIRO FUJIMOTO"'
Autor:
Masaki Shiota, Shota Nemoto, Ryo Ikegami, Shuichi Tatarano, Toshiyuki Kamoto, Keita Kobayashi, Hideki Sakai, Tsukasa Igawa, Tomomi Kamba, Naohiro Fujimoto, Akira Yokomizo, Seiji Naito, Masatoshi Eto
Publikováno v:
BJC Reports, Vol 2, Iss 1, Pp 1-8 (2024)
Abstract Background The predictive power of the treatment efficacy and prognosis in primary androgen deprivation therapy (ADT) for advanced prostate cancer is not satisfactory. The objective of this study was to integrate genetic and clinical data to
Externí odkaz:
https://doaj.org/article/db4199766c0a496080e9b53340cb9acc
Autor:
Akinori Minato, Nobuki Furubayashi, Yujiro Nagata, Toshihisa Tomoda, Hiroyuki Masaoka, Yoohyun Song, Yoshifumi Hori, Keijiro Kiyoshima, Takahito Negishi, Kentaro Kuroiwa, Narihito Seki, Ikko Tomisaki, Kenichi Harada, Motonobu Nakamura, Naohiro Fujimoto
Publikováno v:
Current Oncology, Vol 31, Iss 2, Pp 862-871 (2024)
Subtype of urothelial carcinoma (SUC), defined here as urothelial carcinoma with any histologic subtype or divergent differentiation, is a clinically aggressive disease. However, the efficacy of enfortumab vedotin (EV) against SUC remains unclear. He
Externí odkaz:
https://doaj.org/article/090e7c2b79cf474b85e1f11873b1d392
Autor:
Yujiro Nagata, Akinori Minato, Hisami Aono, Rieko Kimuro, Katsuyoshi Higashijima, Ikko Tomisaki, Kenichi Harada, Hiroshi Miyamoto, Naohiro Fujimoto
Publikováno v:
International Journal of Molecular Sciences, Vol 25, Iss 19, p 10348 (2024)
Locally advanced or metastatic urothelial carcinoma is a genomically and molecularly heterogeneous disease associated with various clinical outcomes. We aimed to evaluate the association between the status of p53/FGFR3 expression and the efficacy of
Externí odkaz:
https://doaj.org/article/bf6a410875db44b690117811602fc022
Autor:
Mirii Harada, Ikko Tomisaki, Shohei Shimajiri, Keisuke Kuretake, Kenichi Harada, Naohiro Fujimoto
Publikováno v:
IJU Case Reports, Vol 6, Iss 6, Pp 386-389 (2023)
Introduction Small cell carcinoma (SCC) of the kidney is extremely rare. Although the majority of patients with advanced renal small cell carcinoma were treated with a combination of cisplatin and etoposide, the efficacy was limited. We report the fi
Externí odkaz:
https://doaj.org/article/8db9b615c05e471ea15400138c6d7193
Autor:
Kanako Hara, Kei Yamasaki, Masahiro Tahara, Rieko Kimuro, Yudai Yamaguchi, Yu Suzuki, Hiroki Kawabata, Toshinori Kawanami, Naohiro Fujimoto, Kazuhiro Yatera
Publikováno v:
Thoracic Cancer, Vol 12, Iss 5, Pp 720-724 (2021)
Abstract A 78‐year‐old male with renal cell carcinoma was treated with combined immunotherapy of nivolumab and ipilimumab. After four courses of the treatment, a chest computed tomography (CT) revealed newly formed ground‐glass opacities (GGOs)
Externí odkaz:
https://doaj.org/article/797505e4149c436793236a41c21b109f
Publikováno v:
IJU Case Reports, Vol 3, Iss 4, Pp 137-140 (2020)
Introduction Mucinous cystic neoplasms are uncommon among the tumors that develop in the retroperitoneum. We report a case of primary retroperitoneal mucinous cystadenocarcinoma with pathological considerations. Case presentation A 47‐year‐old wo
Externí odkaz:
https://doaj.org/article/a167381befbf44aab095e8c590b2e675
Autor:
Truong-Minh Pham, Tatsuhiko Kubo, Yoshihisa Fujino, Naohiro Fujimoto, Ikko Tomisaki, Akinori Minato, Shinya Matsuda
Publikováno v:
Journal of Epidemiology, Vol 29, Iss 12, Pp 464-470 (2019)
Background: In the present study, we examined the trends of premature mortality due to kidney and bladder cancers among the Japanese population from 1980 through 2010. Methods: Mortality data were obtained from the World Health Organization mortality
Externí odkaz:
https://doaj.org/article/91a53f6724924eeb88040880b9141226
Autor:
Yudai Kudo, Satoshi Endo, Masatoshi Tanio, Tomofumi Saka, Rin Himura, Naohito Abe, Mitsumi Takeda, Eiji Yamaguchi, Yuta Yoshino, Yuki Arai, Hirohito Kashiwagi, Masayoshi Oyama, Akichika Itoh, Masaki Shiota, Naohiro Fujimoto, Akira Ikari
Publikováno v:
International Journal of Molecular Sciences, Vol 23, Iss 22, p 14356 (2022)
Prostate cancer (PC) represents the most common cancer disease in men. Since high levels of androgens increase the risk of PC, androgen deprivation therapy is the primary treatment; however this leads to castration-resistant PC (CRPC) with a poor pro
Externí odkaz:
https://doaj.org/article/da479d7dc909475b94d9061da88aa07e
Autor:
Masaki Shiota, Naohiro Fujimoto, Takashi Matsumoto, Shigehiro Tsukahara, Shohei Nagakawa, Shohei Ueda, Miho Ushijima, Eiji Kashiwagi, Ario Takeuchi, Junichi Inokuchi, Takeshi Uchiumi, Masatoshi Eto
Publikováno v:
Frontiers in Oncology, Vol 11 (2021)
Transforming growth factor-β1 (TGF-β1) plays a dual role in cancer, acting as a tumor suppressor in the early stage of cancer development and as a tumor promoter in the later stage of cancer progression in various cancers. In this study, we investi
Externí odkaz:
https://doaj.org/article/a93856b498c54c75b3be08373029e4a7
Autor:
Masaki Shiota, Naohiro Fujimoto, Kenjiro Imada, Eiji Kashiwagi, Ario Takeuchi, Junichi Inokuchi, Katsunori Tatsugami, Shunichi Kajioka, Takeshi Uchiumi, Masatoshi Eto
Publikováno v:
Frontiers in Oncology, Vol 8 (2018)
Mineralocorticoid receptor (MR) signaling which is closely associated with hypertension plays important roles in resistance to antiandrogen therapy in prostate cancer. However, its impact on the prognosis in androgen-deprivation therapy (ADT) has not
Externí odkaz:
https://doaj.org/article/e88bb3b4e3d1400e92613a10f724dd68